Aitia

GNS Healthcare applies a powerful form of AI called causal machine learning to predict which treatments will work for which patients, accelerating the clinical development of new drugs, and improving individual patient outcomes while reducing the total cost of care. Headquartered in the biotechnology center of Somerville, Massachusetts, our patented REFS™ technology is based on recent breakthroughs in causal machine learning and AI that transforms massive quantities of patient data into in silico patients that simulate clinical trials. These computer models are simulated to discover new drugs for serious diseases, and power up solutions that, biopharmaceutical companies utilize to slow disease progression and improve therapeutic effectiveness. Our platforms and solutions have been validated across oncology, immunology, cardiovascular, metabolic disease, and neurology, etc. and have appeared in over 50 peer-reviewed publications.